

CORRECTION

Open Access



Correction: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

Mamoru Shibata^{1*}, Kazuki Fujita², Eri Hoshino², Kazushi Minami¹, Kenzo Koizumi¹, Satoshi Okada¹ and Fumihiko Sakai³

Correction: *BMC Neurol* 24, 32 (2024)

<https://doi.org/10.1186/s12883-023-03521-y>

Following publication of the original article [1], the authors would like to correct a couple of errors in numerical data under the headings “Effects of CGRP mAbs on MMDs”, “Comparison of the therapeutic effects on MMDs among CGRP mAbs” and Table 1.

Effects of CGRP mAbs on MMDs.

The sentence currently reads:

Significant MMD reductions from baseline to V3 were observed in both EM (9.0 ± 7.3 vs. 19.1 ± 6.1 , $p=0.0001$, Supplementary Fig. 1A) and CM (7.1 ± 4.5 vs. 11.2 ± 4.2 , $p<0.0001$, Supplementary Fig. 1B).

The sentence should read:

Significant MMD reductions from baseline to V3 were observed in both CM (9.0 ± 6.0 vs. 19.1 ± 6.1 , $p=0.0001$, Supplementary Fig. 1A) and EM (6.8 ± 5.2 vs. 11.2 ± 4.2 , $p<0.0001$, Supplementary Fig. 1B).

Comparison of the therapeutic effects on MMDs among CGRP mAbs.

The sentence currently reads:

As shown in Fig. 5A–C, galcanezumab and fremanezumab significantly reduced MMDs after 3 doses (galcanezumab: 7.1 ± 5.8 vs. 14.0 ± 5.9 , $p=0.0001$; fremanezumab: 7.8 ± 5.4 vs. 19.1 ± 5.5 , $p=0.0042$),...

The sentence should read:

As shown in Fig. 5A–C, galcanezumab and fremanezumab significantly reduced MMDs after 3 doses (galcanezumab: 7.1 ± 5.8 vs. 14.0 ± 5.9 , $p=0.0001$; fremanezumab: 7.8 ± 5.4 vs. 12.1 ± 5.5 , $p=0.0042$),...

In Table 1 under column Fremanezumab, $67.2 \pm 2.5.5$ should be changed to 67.2 ± 5.5 .

The original article [1] has been updated.

The online version of the original article can be found at <https://doi.org/10.1186/s12883-023-03521-y>.

*Correspondence:

Mamoru Shibata
mshibata@tdc.ac.jp

¹Department of Neurology, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan

²Saitama International Headache Center, Saitama Neuropsychiatric Institute, Saitama, Japan

³Saitama International Headache Center, Saitama, Japan



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 09 May 2024

retrospective observational cohort study at two Japanese headache centers.
BMC Neurol. 2024;24:32. <https://doi.org/10.1186/s12883-023-03521-y>.

References

1. Shibata M, Fujita K, Hoshino E, et al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.